Travere Therapeutics Acquired | Healthcare M&A Deal

Travere Therapeutics has completed the acquisition of Travere Therapeutics, a healthcare services other business in the United States, for $525,000,000. Travere Therapeutics operates in healthcare services other, with activities tied to therapeutic development and commercialization needs that support broader healthcare M&A objectives. The Travere Therapeutics acquisition fits a healthcare services other acquisition strategy and expands other acquisition capabilities within the healthcare sector. The announced other acquisition is valued over $100M and is structured around financing that includes 0.50% convertible senior notes due 2032, with a supplemental indenture dated May 11, 2026, to support capital structure and future flexibility.